2018 Implementations and Timelines

August 8, 2017
Session 1

Q&A

• Please submit all questions concerning webinar content through the Q&A panel.
• A recording of today’s session, the Q&A, and a copy of the slides will be posted to the NAACCR website in about one week.
Agenda

• 2018 Timeline
  – Lori Havener-NAACCR Program Manager of Standards
• Update on the NAACCR Site-Specific Data Item (SSDI) Taskforce
  – Jennifer Ruhl-Co Chair of the SSDI Task Force
• Q&A
  – Liz Ward- Co Chair of the SSDI Task Force
  – Jim Hofferkamp NAACCR Program Manager of Education and Training

2018 Implementations and Timelines
Lori Havener, CTR
**2018 Implementations and Timelines**

- **AJCC 8th Edition Chapter Updates to Histologies (Release 8/31/17)**
  - Collaborative effort to develop recommendations on eligible histology types for each chapter
  - Completion of this work will impact:
    - Release of a TNM DLL
    - Cancer registry software updates
    - Release of EDITS
    - Solid tumor rules (MP/H rules)
    - Data collection by hospital and central cancer registries

- **ICD-O-3 Histology Revisions (Release 8/1/17)**
  - Collaborative effort to identify new terms used for current codes, new codes, and codes with changes in behavior
  - Completion of this work will impact:
    - Standards Volume II, Chapter 3, standard setter’s reportability table
    - SEER site/histology validation list
    - Release of EDITS
    - Cancer registry software
    - Data collection by hospital and central cancer registries
2018 Implementations and Timelines

• New and Revised Prognostic Data Items (Submit to UDS by 9/1/17)
  – Collaborative effort to develop new site-specific data items and revise existing site-specific data items
  – Completion of this work will impact:
    • Standards Volume II
    • Release of EDITS
    • Cancer registry software
    • Data collection by hospital and central cancer registries

2018 Implementations and Timelines

• MP/H Rules (Release by 11/1/17)
  – New rules for solid tumors (determining multiple primaries and histologies)
  – Completion of this work will impact:
    • Data collection by hospital and central cancer registries
2018 Implementations and Timelines

- SEER Hematopoietic and Lymphoid Database (Release by 11/1/17)
  - Updates based on
    - clarifications received from AJCC 8th Edition hematologic chapter authors
    - Revised WHO Hematopoietic book
  - Completion of this work will impact:
    - Data collection by hospital and central cancer registries

2018 Implementations and Timelines

- SEER Summary Stage 2018 and SEER EOD (Release by 11/1/17)
  - Reflects the changes in AJCC 8th Edition
  - SEER Summary Stage 2018 will be derived from SEER EOD 2018
  - Directly assigned Summary Stage 2018 will be available for registries that do not collect SEER EOD
  - Completion of this work will impact:
    - Data collection by hospital and central cancer registries
2018 Implementations and Timelines

• Standards Volume II (Release by 12/1/17)
  – Data standards and data dictionary
  – Standard setter requirements
  – Completion of this work will impact:
    • Release of EDITS
    • Release of 2018 Implementations and Guidelines document
    • Cancer registry software
    • Data collection by hospital and central cancer registries

2018 Implementations and Timelines

• CoC STORE Manual (Release by 1/1/18)
  – New CoC manual
  – Completion of this work will impact:
    • Data collection by hospital cancer registries
2018 Implementations and Timelines

• EDITS (Release by 1/1/18)
  – Develop edits for new data items, update edit-related tables to accommodate changes to site/histologies, and revisions to T, N, M edits.
  – Completion of this work will impact:
    • Cancer registry software
    • Data collection by hospital and central cancer registries

• 2018 Implementation Guidelines (Release by 3/1/18)
  – Collaborative effort to develop guidelines and recommendations for 2018 implementations.
  – Completion of this work will impact:
    • Cancer registry software
    • Data collection by hospital and central cancer registries
2018 Implementations and Timelines

• Other Activities
  – Cancer registry software
    • CDC NPCR TNM DLL
    • NCI SEER RSA
    • Hospital and central cancer registry software updates
      – EDITS
      – Conversions
      – Labeling and documentation
      – Test phase
  • Data conversions

2018 Implementations and Timelines

• Other Activities
  – Central Registry
    • Update cancer registry software
    • Revise central registry manuals
    • Update manuals for reporting facilities
    • Develop and provide education/training
  – Education/training for hospital and central cancer registries.
Questions?

2018 Implementations and Timelines

Thank You!
Purpose of Group

- Evaluate current structure of Site Specific Factors (SSFs)
- Make recommendations for changes
- Revise codes and coding instructions (as needed)
### Members

<table>
<thead>
<tr>
<th>Jennifer Ruhl (SEER) Co-Chair</th>
<th>Liz Ward (NAACCR) Co-Chair</th>
<th>Jenna Mazreku (California) Co-Chair (first six months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donna Gress (AJCC)</td>
<td>Laura Meyer (AJCC)</td>
<td>Kathleen Thoburn (CoC)</td>
</tr>
<tr>
<td>Mary Brant (California)</td>
<td>Donna Hansen (California)</td>
<td>Marilyn Soccozza (California)</td>
</tr>
<tr>
<td>Sheila Fukumara (Canada)</td>
<td>Iris Chilton (Canada)</td>
<td>Richard Moldwin (CAP)</td>
</tr>
<tr>
<td>Annette Hurlbut (Elekta)</td>
<td>Jim Hofferkamp (NAACCR)</td>
<td>Lori Havener (NAACCR)</td>
</tr>
<tr>
<td>Sandy Jones (NPCR)</td>
<td>Jennifer Seiffert (NPCR)</td>
<td>Michelle Esterly (NPCR)</td>
</tr>
<tr>
<td>Serban Negoita (SEER)</td>
<td>Nicki Schussler (SEER/IMS)</td>
<td></td>
</tr>
</tbody>
</table>

### NAACCR Taskforce Decision

- Discontinue with current SSF approach
- Develop discrete data items
  - More flexibility
  - Different data item lengths
  - Coding actual data item
  - Easier for programmers
  - Easier to retrieve data
Site Specific Factor Data Review

- Priority review
  - Schema discriminators
  - Required for staging
  - Currently required by at least one standard setter
    - Listed in 8th edition as data collection item
    - Not listed in 8th edition

Site Specific Factor Data Review-by the numbers

- Approximately 260 unique CS SSFs
  - 101 discontinued
  - 12 obsolete
  - 147 required
    - Of these, 27 are not required for 1/1/2018+

- Only 120 SSFs brought over from CSv0205
2018 Data Collection

- ALL SSF’s retired
  - Current SSFs and requirements still in effect for all cases diagnosed through 12/31/2017
- Discrete data items go into effect 1/1/2018+
- SSFs being combined when possible
  - Example: Perineural Invasion
    - Collected in several different schemas, not always the same SSF. Will be one data item

General Changes Made

- Data items different lengths
- Data items can include decimal points
- Different coding conventions used to document
  - Recording of actual values, percentages, ranges
  - Recording different definitions of unknown
### Example of Different Coding Values

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>000</td>
<td>Sarcomatoid features not present/not identified</td>
</tr>
<tr>
<td>.1-100.0</td>
<td>Sarcomatoid features .1-100.0%</td>
</tr>
<tr>
<td>R00.1</td>
<td>Sarcomatoid features stated as less than 10%</td>
</tr>
<tr>
<td>R00.2</td>
<td>Sarcomatoid features stated as 10-30% present</td>
</tr>
<tr>
<td>R00.3</td>
<td>Sarcomatoid features stated as greater than 30% to 50% present</td>
</tr>
<tr>
<td>R00.4</td>
<td>Sarcomatoid features stated as greater than 50% to 80% present</td>
</tr>
<tr>
<td>R00.5</td>
<td>Sarcomatoid features stated as greater than 80%</td>
</tr>
<tr>
<td>XXX.6</td>
<td>Sarcomatoid features present, percentage unknown</td>
</tr>
<tr>
<td>XXX.7</td>
<td>Not applicable: Not a renal cell carcinoma morphology</td>
</tr>
<tr>
<td>XXX.8</td>
<td>Not applicable: Information not collected for this case</td>
</tr>
<tr>
<td></td>
<td>(If this information is required by your standard setter, use of code XXX.8 may result in an edit error.)</td>
</tr>
<tr>
<td>XXX.9</td>
<td>Unknown or no information</td>
</tr>
<tr>
<td></td>
<td>Sarcomatoid features not assessed or unknown if assessed</td>
</tr>
</tbody>
</table>

### Example of Different Coding Values

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.1</td>
<td>0.1 or less nanograms/milliliter (ng/ml) (Exact value to nearest tenth of ng/ml)</td>
</tr>
<tr>
<td>0.2-999.9</td>
<td>0.2 –999.9 ng/ml (Exact value to nearest tenth of ng/ml)</td>
</tr>
<tr>
<td>XXX.1</td>
<td>1,000 ng/ml or greater</td>
</tr>
<tr>
<td>XXX.8</td>
<td>Test ordered, results not in chart</td>
</tr>
<tr>
<td>XXX.9</td>
<td>Not documented in medical record</td>
</tr>
<tr>
<td></td>
<td>PSA lab value not assessed or unknown if assessed</td>
</tr>
</tbody>
</table>
Example of Using New Data Items

• Prostate Specific Antigen (PSA)
  – Value of 5.2

• In CS, would have to code 052
• Now, code _ _5.2

Updating the SSFs to Discrete Data Items

• Harmonize with AJCC 8th edition
  – Donna Gress: liaison between SSDI & AJCC
• Harmonize with updated CAP guidelines
  – Richard Moldwin: liaison between SSDI & CAP
  – Data items developed using CAP guidelines checklist
  – Codes and coding instructions align with CAP checklists
    (as much as possible)
Current Status

• ~150 data items developed for 2018
  – All reviewed and approved by SSDI for the following
    (information needed for NAACCR Volume II):
    • Name
    • Rationale/description of data item
    • Codes/code descriptions
  – Approximately 140 approved and 10 pending
    review/approval by UDS

New Data Items for 2018

• Required for Staging-14 new data items
  – Breast (1)
  – CLL/SLL (5)
  – Esophagus (1)
  – Melanoma Skin (1)
  – Plasma cell myeloma/multiple myeloma (4)
  – Testis (2)
New Data Items for 2018

- Schema Discriminators
  - Schema discriminator 1
  - Schema discriminator 2
  - Schema discriminator 3

New Schema Discriminators

- Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck (Chapter 6)
- HPV-p16 (Chapters 10 and 11)
- Esophagus (Chapter 16)
- Urethra/Prostatic Urethra (Chapter 63)
- Thyroid/Thyroglossal Duct (Chapters 73 and 74)
Other New Data Items

- Breast (14)
  - Current SSFs 8-16 being retired (HER2 SSFs)
  - ER/PR (4 new data items)
  - HER2 (5 new data items)
  - Ki-67 (1 new data item)
  - Oncotype Dx (4 new data items—one required for staging)

- Note: At this time, standard setter requirements for these data items are not known

Grade

- Current SSFs that collect chapter specific grades (e.g., Breast, Prostate, Soft Tissue, Appendix) will be retired
- Three new grade data items (effective 1/1/2018)
  - Grade Clinical
  - Grade Pathological
  - Grade Post-neoadjuvant
Grade

- New grade data items will
  - Incorporate chapter specific grading systems (when applicable)
  - Allow for coding of grade at different points of patient care
  - Historical/standard definitions when specific grading systems not available or not applicable

- Note: The new grade data items are still being developed. New general grade coding instructions PLUS chapter specific grading instructions will be included

Grade-Breast

<table>
<thead>
<tr>
<th>G</th>
<th>G Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>G1: Low combined histologic grade (favorable), SBR score of 3–5 points</td>
</tr>
<tr>
<td>2</td>
<td>G2: Intermediate combined histologic grade (moderately favorable); SBR score of 6–7 points</td>
</tr>
<tr>
<td>3</td>
<td>G3: High combined histologic grade (unfavorable); SBR score of 8–9 points</td>
</tr>
<tr>
<td>A</td>
<td>Well differentiated</td>
</tr>
<tr>
<td>B</td>
<td>Moderately differentiated</td>
</tr>
<tr>
<td>C</td>
<td>Poorly differentiated</td>
</tr>
<tr>
<td>D</td>
<td>Undifferentiated, anaplastic</td>
</tr>
<tr>
<td>9</td>
<td>Grade cannot be assessed; Unknown (GX)</td>
</tr>
</tbody>
</table>
Grade:

- Standard grade table now used for AJCC chapters that have no grading system listed AND for those primary site/histologies combinations not covered in 8th edition

<table>
<thead>
<tr>
<th>Code</th>
<th>Grade/Cell Type Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Well differentiated</td>
</tr>
<tr>
<td>B</td>
<td>Moderately differentiated</td>
</tr>
<tr>
<td>C</td>
<td>Poorly differentiated</td>
</tr>
<tr>
<td>D</td>
<td>Undifferentiated, anaplastic</td>
</tr>
<tr>
<td>9</td>
<td>Grade cannot be assessed; Unknown</td>
</tr>
</tbody>
</table>

Other SSDI tasks

- Assisted AJCC with new/updated AJCC data items
  - Post-neoadjuvant T, N, M, Stage Group, Grade
  - T & N Suffixes (multiple, fna, sentinel node biopsy)
    - Clinical and Pathological descriptors no longer collected for cases diagnosed 1/1/2018+
  - T, N, M, Stage Group (both clin and path) data items: expanded data lengths

  - Note: AJCC will be providing information/guidelines on these data items
Pending for 2018 Data Collection

- Finalize coding instructions for ALL data items
- Standard setter requirements for 2018 **TO BE DETERMINED**
  - Standard setter requirements required by 10/1/2017

Pending for 2019 Data Collection

- Prioritize and develop
  - Review data items listed in 8th edition
  - Other new data items for 2019
- Update/expand data items released in 2018 (when applicable)
- Update/revise/rename *CS Part I Section II* (extended information on SSFs/discrete data items)
Questions?

Update on the NAACCR Site-Specific Data Item (SSDI)

---

**Perspective**

- AJCC 8th edition
- Summary stage
- EOD
- SSDI’s
- ICD O 3
- Solid Tumor Rules
- Hematopoietic Rules
- Volume II
- Edits

"About that last one..."
Thank You!

Jim Hofferkamp jhofferkamp@naaccr.org